Please login to the form below

Not currently logged in


This page shows the latest thalidomide news and features for those working in and with pharma, biotech and healthcare.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno

Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

Latest news

More from news
Approximately 3 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...